VRTX Vertex Pharmaceuticals Incorporated

168.16
+1.19  (+1%)
Previous Close 166.97
Open 169.96
Price To Book 9.69
Market Cap 42991262454
Shares 255,656,889
Volume 3,195,691
Short Ratio
Av. Daily Volume 1,373,353

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 positive data released November 27, 2018. 14% improvement in ppFEV1 cf placebo.
VX-659 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation (F508del/Min)
PDUFA date under priority review February 28, 2017. Approval announced February 12, 2018.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - Two Copies of the F508del Mutation
Phase 2 data released July 18, 2017. ppFEV1 of 12.0 percentage points.
VX-440 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Approved December 29, 2014.
KALYDECO
Cystic fibrosis (CF) ages 6 and older who have the R117H mutation
Phase 2 primary endpoint met - January 25, 2017.
VX-150
Osteoarthritis
CRL issued February 5, 2016.
KALYDECO (ivacaftor)
Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations.
Approved July 2, 2015.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation
Approved March 17, 2015.
KALYDECO (ivacaftor)
Children ages 2 to 5 with cystic fibrosis who have the G551D or one of the eight additional gating mutations
NDA filing due 1Q 2018.
ORKAMBI
Two Copies of the F508del Mutation - children ages 2 to 5
Phase 3 data released October 25, 2017 - primary endpoint not met.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in a gating mutation
Phase 3 trial terminated August 2016
VX-661
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in minimal CFTR Function
Approved September 28, 2016.
ORKAMBI
Cystic fibrosis (CF) ages 6-11 who have F508del mutation
Phase 2 data released July 18, 2017. ppFEV1 of 9.7 percentage points.
VX-152 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 2 data released December 18, 2018. Primary endpoint met.
VX-150
Neuropathic pain
Phase 2b data due 1H 2019.
VX-150
Acute pain following bunionectomy surgery
Phase 3 data released March 6, 2019 - primary endpoint met. Further 24-week data due 2Q 2019.
VX-445 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have two copies of the F508del mutation
Phase 3 positive data released November 27, 2018. 10% improvement in ppFEV1 cf placebo.
VX-659 in combination with tezacaftor and ivacaftor
Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Phase 3 data released March 6, 2019 - primary endpoint met. Further 24-week data due 2Q 2019.
VX-445 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have one copy of the F508del mutation and one minimal function mutation
Phase 1/2 trial first patient enrolled - noted February 25, 2019.
CTX001
Sickle cell disease
Phase 1/2 trial first patient infused - noted February 25, 2019.
CTX001
Beta-thalassemia
FDA Approval announced August 7, 2018.
Ivacaftor
Cystic fibrosis (CF) ages 2 to 5.
Approval announced August 15, 2018.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 1-2.
sNDA filing due late 2018.
Ivacaftor
Cystic Fibrosis (6-12 mths)
sNDA filing due late 2018.
Tezacaftor and ivacaftor
Cystic Fibrosis (Age 6-11)
Phase 2 monotherapy trial to commence 2H 2019.
VX-561
Cystic fibrosis who have a gating mutation